Ten-year follow-up results of perioperative chemotherapy with doxorubicin and ifosfamide for high-grade soft-tissue sarcoma of the extremities: Japan Clinical Oncology Group study JCOG0304.
Adult
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Chemotherapy, Adjuvant
Clinical Trials as Topic
Doxorubicin
/ administration & dosage
Drug Administration Schedule
Extremities
/ pathology
Female
Follow-Up Studies
Humans
Ifosfamide
/ administration & dosage
Japan
Male
Odds Ratio
Perioperative Period
Sarcoma
/ drug therapy
Soft Tissue Neoplasms
/ drug therapy
Survival Rate
Treatment Outcome
10-year follow-up
Doxorubicin and ifosfamide
Extremity
Perioperative chemotherapy
Soft tissue sarcoma
Survival
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
06 Sep 2019
06 Sep 2019
Historique:
received:
27
05
2019
accepted:
30
08
2019
entrez:
8
9
2019
pubmed:
8
9
2019
medline:
19
2
2020
Statut:
epublish
Résumé
Soft-tissue sarcomas (STS) are rare malignant tumors those are resistant to chemotherapy. We have previously reported the 3-year follow-up result on the efficacy of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-risk STS of the extremities (JCOG0304). In the present study, we analyzed the 10-year follow-up results of JCOG0304. Patients with operable, high-risk STS (T2bN0M0, AJCC 6th edition) of the extremities were treated with 3 courses of preoperative and 2 courses of postoperative chemotherapy, which consisted of 60 mg/m A total of 72 patients were enrolled between March 2004 and September 2008, with 70 of these patients being eligible. The median follow-up period was 10.0 years for all eligible patients. Local recurrence and distant metastasis were observed in 5 and 19 patients, respectively. The 10-year PFS was 65.7% (95% CI: 53.4-75.5%) with no PFS events being detected during the last 5 years of follow-up. The 10-year overall survival was 78.1% (95% CI: 66.3-86.2%). Secondary malignancy was detected in 6 patients. The subgroup analysis demonstrated that there was significant difference in survival with regard to primary tumor size. Only a few long-term results of clinical trials for perioperative chemotherapy treatment of STS have been reported. Our results demonstrate that the 10-year outcome of JCOG0304 for patients with operable, high-risk STS of the extremities was stable and remained favorable during the last 5 years of follow-up. This trial was registered at the UMIN Clinical Trials Registry as C000000096 on August 30, 2005.
Sections du résumé
BACKGROUND
BACKGROUND
Soft-tissue sarcomas (STS) are rare malignant tumors those are resistant to chemotherapy. We have previously reported the 3-year follow-up result on the efficacy of perioperative chemotherapy with doxorubicin (DXR) and ifosfamide (IFM) for high-risk STS of the extremities (JCOG0304). In the present study, we analyzed the 10-year follow-up results of JCOG0304.
METHODS
METHODS
Patients with operable, high-risk STS (T2bN0M0, AJCC 6th edition) of the extremities were treated with 3 courses of preoperative and 2 courses of postoperative chemotherapy, which consisted of 60 mg/m
RESULTS
RESULTS
A total of 72 patients were enrolled between March 2004 and September 2008, with 70 of these patients being eligible. The median follow-up period was 10.0 years for all eligible patients. Local recurrence and distant metastasis were observed in 5 and 19 patients, respectively. The 10-year PFS was 65.7% (95% CI: 53.4-75.5%) with no PFS events being detected during the last 5 years of follow-up. The 10-year overall survival was 78.1% (95% CI: 66.3-86.2%). Secondary malignancy was detected in 6 patients. The subgroup analysis demonstrated that there was significant difference in survival with regard to primary tumor size.
CONCLUSIONS
CONCLUSIONS
Only a few long-term results of clinical trials for perioperative chemotherapy treatment of STS have been reported. Our results demonstrate that the 10-year outcome of JCOG0304 for patients with operable, high-risk STS of the extremities was stable and remained favorable during the last 5 years of follow-up.
TRIAL REGISTRATION
BACKGROUND
This trial was registered at the UMIN Clinical Trials Registry as C000000096 on August 30, 2005.
Identifiants
pubmed: 31492159
doi: 10.1186/s12885-019-6114-2
pii: 10.1186/s12885-019-6114-2
pmc: PMC6728960
doi:
Substances chimiques
Doxorubicin
80168379AG
Ifosfamide
UM20QQM95Y
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
890Subventions
Organisme : National Cancer Center Research and Development Fund
ID : 29-A-3
Organisme : Japan Agency for Medical Research and Development
ID : JP18ck0106336
Références
Jpn J Clin Oncol. 2015 Jun;45(6):555-61
pubmed: 25838293
Lancet Oncol. 2012 Oct;13(10):1045-54
pubmed: 22954508
Jpn J Clin Oncol. 2009 Apr;39(4):271-3
pubmed: 19155282
J Clin Oncol. 1997 Jan;15(1):350-62
pubmed: 8996162
Oncology. 2003;65 Suppl 2:80-4
pubmed: 14586155
JAMA Oncol. 2018 Apr 01;4(4):483-492
pubmed: 29450452
Cancer. 2008 Aug 1;113(3):573-81
pubmed: 18521899
Lancet Oncol. 2017 Jun;18(6):812-822
pubmed: 28499583
World J Surg Oncol. 2016 Apr 18;14:110
pubmed: 27091124
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv268-iv269
pubmed: 30285214
World J Surg Oncol. 2018 Aug 10;16(1):162
pubmed: 30097070
Jpn J Clin Oncol. 2014 Aug;44(8):765-9
pubmed: 24916336
J Clin Oncol. 2012 Mar 10;30(8):850-6
pubmed: 22312103
J Clin Oncol. 2001 Mar 1;19(5):1238-47
pubmed: 11230464
BMC Cancer. 2019 Sep 6;19(1):890
pubmed: 31492159
Ann Oncol. 2016 Dec;27(12):2283-2288
pubmed: 27733375